ArticleVaccines2025
HPV Vaccination and CIN3+ Among Women Aged 25-29 Years in Northern Norway, 2010-2024: A Population-Based Time-Series Analysis.
Article in Vaccines, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Long-Term Regional Pathology-Detection Trends in High-Grade Cervical Lesions and Cervical Squamous Cell Carcinoma Among Women Aged 40-69 Years in Northern Norway, 1998-2025.Diagnostics (Basel, Switzerland) · 2026Article
- Cervical Cancer Screening: Histologic Outcomes of HPV-Negative HSIL/ASC-H Cytology in a Tertiary Referral Cohort in Northern Thailand.Medicina (Kaunas, Lithuania) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
objectivesCervical intraepithelial neoplasia grade 3 and worse (CIN3+) is a robust surrogate for cervical cancer risk. In Norway, organized cervical screening starts at 25 years of age (25-69 years). Norway introduced school-based HPV vaccination with the quadrivalent vaccine for 12-year-old girls in 2009 (birth cohorts ≥ 1997) with high 3-dose completion, and a catch-up program with the bivalent vaccine for women born 1991-1996 in 2016-2019 with lower uptake. We assessed whether increasing birth-cohort vaccination coverage (defined as ≥1 dose) was followed by reductions in CIN3+ at the age of entry to organized screening (25-29 years).
methodsWe conducted a retrospective, population-based time-series of women aged 25-29 years in Troms and Finnmark screened in 2010-2024. CIN3+ was counted per unique woman and expressed per 1000 screened women per year. Cohort-level vaccination exposure was proxied by birth-year eligibility and national coverage (≥1 dose) by calendar year. Temporal trends were assessed using segmented linear regression (2010-2017; 2017-2024).
resultsAmong 42,253 screening tests, 865 women had CIN3+. CIN3+ rates were stable in 2010-2016 (≈15-24 per 1000), peaked in 2017-2018 (≈26-28 per 1000), and declined to 6.6 per 1000 in 2024 (~75% reduction from the peak). The 2010-2017 trend was not significant (
conclusionsAs vaccinated birth cohorts-especially those vaccinated before sexual debut-entered organized screening at age 25, CIN3+ in women aged 25-29 years fell markedly. Estimates are based on coverage defined as ≥1 dose; future linkage to individual dose data and HPV type-specific CIN3+ is warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.